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Background: Despite inducing a sustained increase in CD4+ T cell counts, intermittent recombinant IL-2 (rIL-2)
therapy did not confer a better clinical outcome in HIV-infected patients enrolled in large phase III clinical trials
ESPRIT and SILCAAT. Several hypotheses were evoked to explain these discrepancies. Here, we investigated the
impact of low and high doses of IL-2 in Rhesus macaques of Chinese origin infected with SIVmac251 in the
absence of antiretroviral therapy (ART).
Results: We demonstrated that rIL-2 induced a dose dependent expansion of CD4+ and CD8+ T cells without
affecting viral load. rIL-2 increased CD4 and CD8 Treg cells as defined by the expression of CD25highFoxP3+CD127low.
We also showed that rIL-2 modulated spontaneous and Fas-mediated CD4+ and CD8+ T cell apoptosis. The
higher dose exhibited a dramatic pro-apoptotic effect on both CD4+ and CD8+ T cell populations. Finally, all the
animals treated with rIL-2 developed a wasting syndrome in the month following treatment simultaneously to a
dramatic decrease of circulating effector T cells.
Conclusion: These data contribute to the understanding of the homeostatic and dosage effects of IL-2 in the
context of SIV/HIV infection.
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Progressive decrease in the number of CD4+ T lympho-
cytes is the hallmark of HIV (Human Immunodeficiency
Virus) or SIV (Simian Immunodeficiency Virus) infec-
tion. During this chronic infection, CD4+ T cell loss,
generalized immune activation and increased susceptibil-
ity to apoptosis result in impaired T cell homeostasis
and subsequent development of opportunistic infections
[1]. Mechanisms leading to CD4+ T cell depletion are
not completely understood yet but viral replication plays
a key role in this process. Highly Active Antiretroviral
therapy (HAART), by allowing virological suppression,
significant rise in CD4+ T cell counts and decrease in
apoptosis sensitivity, has dramatically improved clinical
outcome for HIV patients. However, this treatment par-
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reproduction in any medium, provided the ordysregulation and, in addition, implies risk of drug re-
sistance and long terms toxicity [2,3]. This has led to
evaluate therapeutic strategies that could reinforce
HAART effect or even delay the initiation of antiretro-
viral treatment. The best studied of these therapeutic
approaches is intermittent administration of interleukin-
2 (IL-2).
IL-2 is an autocrine T cell growth factor mainly pro-
duced by activated T cells and implicated in the homeo-
stasis and differentiation of Th1, Th2, Th17 and
regulatory T cell subsets. In HIV infection, due to pro-
gressive loss of CD4+ T cells, levels of IL-2 are reduced.
This progressive decrease of IL-2 producing CD4+ T
cells has been directly correlated with activation state
and susceptibility to apoptosis of these cells [4-7]. More-
over, IL-2 was found to improve survival of HIV
patients’ T cells ex vivo through the upregulation of the
anti-apoptotic protein Bcl-2 [8-10]. Partial restoration of
IL-2 producing CD4+ T cell pool is observed following
treatment with HAART [11]. On the other hand, IL-2
has also been shown to play a key role in pro-apoptoticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.


























Figure 1 Human rIL-2 does not affect viral load. Four Rhesus
macaques were infected with the pathogenic SIVmac251 strain and
then treated during chronic phase with human rIL-2 (low dose: О,Δ
or high dose: ●,▲). Each symbol represents one monkey. Viral load
(copies/ml) was quantified by RT-PCR at the day of treatment and
thereafter. Euthanasia date is represented.
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undergo Activation-Induced Cell Death (AICD), a
process that is Fas-mediated and serves as a feedback
regulation of clonal expansion [12]. Mice deficient for
IL-2 develop lymphoproliferation and autoimmune dis-
eases rather than immunodeficiencies [13]. IL-2 has also
been shown to induce directly the expression of pro-
grammed death (PD)-1 molecule and its ligand PD-L1,
negative regulatory members of the B7 family that play
an important role in peripheral tolerance [14]. In
addition, IL-2, by favoring viral replication in vitro, may
induce apoptosis in productively HIV/SIV-infected T
cells [15]. IL-2 immunotherapy has been extensively
studied in phase I/II and III studies. Intermittent treat-
ment with IL-2 induces significant and sustained rise in
CD4+ T cell counts [16-19]. In particular, recombinant
IL-2 therapy raised naïve and central memory CD4+ T
cells [20]. Analysis of T cell populations, using BrdU la-
beling in HIV patients treated with IL-2, revealed a
decreased sensitivity to apoptosis of CD4+ T cells [21].
In addition, in vivo administration of IL-2 was shown to
induce expansion of a CD4 T cell population that
expressed CD45RO, CD25 and FoxP3 at high levels but
exerted weak suppressive activity and were, thus, not
considered as regulatory T cells (Treg) [22]. On the
other hand, a recent study highlighted this point, show-
ing that IL-2 therapy led to expansion of two distinct
CD4+ CD25high T cell populations that could suppress
effector cells proliferation in vitro [23]. This observation
may partially explain the disappointing results of the
large phase III trials SILCAAT and ESPRIT. In these
studies, although the average CD4+ T cell counts were
significantly higher in IL-2 arms, IL-2 plus HAART
yielded no added clinical benefit as compared with
HAART alone [24].
Here, in order to better understand effects of IL-2 on
T lymphocytes populations, we used Rhesus macaques
of Chinese origin infected with SIVmac251 treated with
human recombinant IL-2 (rIL-2) in the absence of
Highly Active Anti-Retroviral Therapy (HAART). We
showed that IL-2 immunotherapy exerted dose
dependent effects on several immunological parameters
without affecting viral load. Treatment with rIL-2
increased CD4+ and CD8+ T cell counts in a dose
dependent manner and induced CD4 and, more interest-
ingly, CD8 Treg as defined by the expression of
CD25highFoxP3+CD127low. We also showed that IL-2
had a dual effect on spontaneous and Fas-induced apop-
tosis of CD4+ and CD8+ T cells with low dose exerting
an anti-apoptotic effect whereas high dose exhibited a
dramatic pro-apoptotic effect on both CD4+ and CD8+
T cell populations. Finally, all the animals treated with
rIL-2 developed a wasting syndrome in the month fol-
lowing treatment.Results
Human rIL-2 transiently increases CD4 and CD8 T cell
counts in a dose-dependent manner
Rhesus macaques infected with SIVmac251 at steady
state of chronic phase (four months post infection),
received rIL-2 either at low dose (1.4x105 UI/kg body
weight) (#056212 and #056216) or at higher dose (6.105
UI/kg body weight) (#056230 and #056238) subcutane-
ously daily for 5 days.
Hematological and physiological parameters such as
platelet, erythrocyte and neutrophil counts, hematocrit,
temperature, weight were followed and remained un-
changed during IL-2 cycle (see Additional file 1). Viral
load was followed in all 4 animals and was not affected
by rIL-2 treatment at either high or low dose (Figure 1).
However, after one month, all treated animals developed
a wasting syndrome with weight loss and diarrhea and
were euthanized. Therefore, for obvious ethical reasons,
no more animals were included in this protocol.
Treatment with rIL-2 increased dramatically CD4+
and CD8+ T cell counts in a dose-dependent manner
while CD20+ B cell counts remained unchanged (Figure 2).
In animals treated with low doses, absolute peripheral
CD4+ T cell counts rose from 450 and 560 cells/mm3 (be-
fore treatment) to 530 cells/mm3 and 970 cells/mm3 (at
day 7) while those treated at the highest dose, experienced
an increase from 690 and 815 to 1800 and 1160 cells/mm3,
respectively.
In addition, the effect of rIL-2 treatment on CD8 T cell
counts was even more pronounced with 2.6 and 1.4 fold
increases from baseline in the two animals treated at low
dose (Δcounts = +1235 and +2045 cells/mm3) and 7.6
Figure 2 Human rIL-2 transiently increases CD4+ and CD8+ T cell counts in a dose-dependent manner. Percentages and counts of
peripheral blood (A) CD4+, (B) CD8+ T cells and (C) CD20+ B cells were measured at day 0, 7, 15 and 45 after IL-2-treatment (low dose: О,Δ or
high dose: ●,▲).
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(Δcounts=+4545 and +3285 cells/mm3). CD4+ and CD8+
changes were transient and T cell counts returned to base-
line at day 15. In control SIV-infected Rhesus macaques
who received a placebo (NaCl) (n=5), CD4 and CD8 T cell
counts remained stable during the same period of time
(data not shown).
At day 45, all animals experienced a drastic CD4 T cell
lymphopenia (Δcounts =−20 and −290 cells/mm3 in ani-
mals treated with low dose and −450 and −425 cells/
mm3 and in animals treated with high dose) whereasCD8 lymphopenia was only observed in recipients of
highest dose of rIL-2 (Δcounts =−335 and −695 cells/
mm3) (Figure 2).
Human rIL-2 has a differential and dose-dependent effect
on CD4 and CD8 T cell subpopulations
We next sought to determine the effects of rIL-2 on T
cell subpopulations defined by the expression of
CD45RA and CD62L. In this analysis, CD45RA+CD62L+
were identified as naïve T cells, CD45RA-CD62L+ were
identified as central memory T cells, CD45RA-CD62L-
B C
A
Figure 3 Human rIL-2 has a differential, dose-dependent effect on CD4+ and CD8+ T cell subsets. (A) Gating strategy to identify naive (N),
central memory (CM), effector memory (EM) and terminal differenciated (TD) T lymphocytes. Cells were first gated on side and forward scatter
parameters (gate R1) and further gated on CD4+ (or CD8+) T cells (gate R2). Thereafter, CD4+ (or CD8+) T cell subsets were analyzed for the
expression of CD45RA and CD62L molecules. CD45RA+CD62L+ were identified as naive, CD45RA-CD62L+ as central memory (CM), CD45RA-CD62L-
as effector memory (EM) and CD45RA+CD62L- as terminal differentiated (TD) T cells. (B) Percentages and counts of each CD4+ T cell
subpopulation were followed in IL-2-treated animals - low dose (ОΔ) or high dose (●▲) (C) Similarly, percentages and counts of each CD8+ T cell
subpopulation were followed in IL-2-treated animals - low dose (ОΔ) or high dose (●▲).
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CD62L- were identified as terminal differentiated T cells
(figure 3A). No significant differences between controls
(n = 5) and IL-2 treated animals (n = 4) were seen atFigure 4 Human rIL-2 transiently increases peripheral blood CD4+ an
the identification of Treg cells. Cells were first gated on side and forward sc
(gate R2) to analyze CD25 and FoxP3 expression. CD4+FoxP3+CD25high or C
CD4+FoxP3+CD25highCD127low or CD8+FoxP3+CD25highCD127low were iden
peripheral blood CD4+CD25high and CD8+CD25 high cells in IL-2-treated ma
days 0, 7 and 45 after IL-2 treatment. (C) Percentages and counts of CD4 o
#056216 – high dose #056230, #056238) at day 0, 7 and 45 after IL-2 treatmbaseline (data not shown). High dose of rIL-2 led to a
dramatic increase of frequency and absolute counts of
naïve CD4 T cell at day 7 (Δ%=+25.9 and 39.4%,
Δcounts = +765 and 530 cells/mm3). In contrast, ind CD8+ Tregs in a dose-dependent manner. (A) Gating strategy for
atter parameters (gate R1) and further gated on CD4+ T cells
D8+FoxP3+CD25high (R3) were then analyzed for CD127 expression.
tified as CD4 or CD8 Tregs respectively. (B) Percentages and counts of
caques (low dose, #056212, #056216 – high dose, #056230, #056238) at
r CD8 Tregs in IL-2-treated macaques (low dose #056212,
ent.
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absolute counts of naïve CD4+ T cells decreased at day 7
after treatment (Δ%=−10.2 and −47.3%, Δcounts =−43
and −220 cells/mm3).
As seen in figure 3B, low dose of rIL-2 increased abso-
lute counts and percentages of effector memory popula-
tions at day 7 from 68 and 16% to 77 and 35%. This
effect was even more pronounced in central memory
CD4+ T cells as this subpopulation accounted from 10
and 14% to 18 and 44% , respectively, of circulating CD4+ T
cells. Animals treated with high dose of rIL-2 also showed
an increase in proportion of central memory CD4+ T cells
(Δ%=+20.3 and 3.8%) but not effector memory T cells. In
addition, high dose of rIL-2 also exerted a “long term” effect
on central memory CD4+ T cells as proportion of this sub-
population increased by 25.5 and 24.1% in the two animals
at day 45.
Finally, terminally differentiated CD4+ T cells were
drastically depleted at day 45 after treatment, whatever
the dose of rIL-2 used, with absolute counts remaining
under 10 cells/mm3 corresponding to 5.3% and 35.7%
decreases for low and high dose respectively (Figure 3B).
High and low dose of rIL-2 therapy exhibited only
modest changes in distribution of CD8+ T populations
at day 7. Percentages of effector memory CD8 T cells
increased by 5.3 and 12.1% in low and and 11.1 and
2.2% in high dose treated animals. Similarly to its effect
on CD4 T cell populations, high rIL-2 dose seemed to
exert a more long term effect on central memory CD8 T
cell pool as it increased from 7.8 and 16.1% before treat-
ment to 33.7 and 38.4% at day 45.Figure 5 Human rIL-2 transiently increases proliferation of CD4+ T ce
(top panel). Ki67 expression was then assessed in each CD4+ T cell subset (
IL-2-treated macaques were #056212, #056216 (low dose) and #056230, #05Thus, in SIV-infected Rhesus macaques, rIL-2 treat-
ment had a differential, dose-dependent effect on T cell
populations, high dose allowing expansion of both naïve
and central memory CD4 T cell subpopulations and low
dose only exerting its effect on CD4 T cell memory sub-
sets (central and effector). High and low dose both
seemed to induce a drastic depletion of terminally differ-
entiated CD4+ T cells at day 45 after treatment. The im-
pact of rIL-2 treatment on distribution of CD8+ T cells
was restricted to effector memory subpopulation what-
ever the dose injected with high dose having a slight ef-
fect on long term central memory CD8 T cells
expansion.
Human rIL-2 transiently increases peripheral blood CD4+
and CD8+ tregs in a dose-dependent manner
We evaluated the frequencies of CD4+ CD25high and
CD8+ CD25high in IL-2 recipients (Figure 4B). Treatment
with rIL-2 induced a transient increase in CD4+
CD25high (Δ%=+8.9 and +5.2%, and +8.7 and +9% at
low and high doses, respectively) and CD8+ CD25high
populations (Δ%=+3.5 and +6.6%, and +4.8 and +11.8%
at low and high doses, respectively). At day 45, fre-
quency of CD8+ CD25high population returned to base-
line levels whereas CD4+ CD25high subset remained
higher than pretreatment values (Δ%=+5.3 and +4.5%
and +8.15 and +4% in animals treated with low and high
doses, respectively).
As CD25high cells could be activated cells or Tregs, we
defined CD4+ Tregs as CD4+ FoxP3+ CD25high CD127low
cells and CD8+ Tregs as CD8+ FoxP3+ CD25highll subset. Ki67 expression was measured intracellularly in CD4+ T cells
N, CM, EM or TD) at days 0 and 7 after IL-2 treatment (bottom panel).
6238 (high dose).
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low dose of rIL-2 provoked a robust increase in CD4+
Treg subset frequency (Δ%=+2.5 and +4.8%) and counts
at day 7. This frequency then returned to basal levels at
day 45. When macaques were treated with high dose of
rIL-2, no increase in frequency of CD4+ Treg subset could
be observed at day 7 (Δ%=−0.1 and −1.9%). In contrast,
peripheral CD8+ Treg population was expanded at day 7
after rIL-2 injection, whatever the dose used (Figure 4C –
bottom panel) by a 1.5 to 6.6 fold.
Human rIL-2 transiently increases proliferation and
activation of CD4+ and CD8+T cells
Next, we evaluated the proportion of proliferating CD4+
and CD8+ T cells as assessed by the percentages of T
cells expressing nuclear Ki67 Antigen (figures 5 and 6).
This revealed a robust and transient rIL-2-associated in-
crease in Ki67 expression in peripheral CD4+ (Figure 5 –
top panel) and CD8+ T cells (Figure 6 – top panel).
Consistent with the results obtained with global T cell
counts, rIL-2 effect on proliferation seemed to be dose-
dependent. Indeed, in animals treated with low rIL-2
dose, we observed an increase of Ki67-expressing CD4+
T cells from 17.7 and 6.8% before treatment to 25.7 and
12% at day 7 (1.4 and 1.7 fold increase respectively).
Using high dose of rIL-2, Ki67 expressing CD4+ T cell
population rose from 6.8 and 4.8% before treatment to
23 and 10.2% at day 7 (3.4 and 2.1 fold increase respect-
ively) (Figure 5 – top panel).
Similarly, for CD8+ T cells, rIL-2 treatment transiently
increased frequency of Ki67 expressing CD8+ T cells atFigure 6 Human rIL-2 transiently increases proliferation of CD8+ T ce
(top panel). Ki67 expression was then assessed in each CD8+ T cell subset (
IL-2-treated macaques were #056212, #056216 (low dose) and #056230, #05day 7 by a 1,8 to 3,3 factor when used at low dose while
this increase was up to 13 fold when animals were trea-
ted with high dose of rIL-2 (Figure 6 – top panel).
We then assessed cycling cells within each of the CD4+
and CD8+ T cell subsets before and at day 7 after treat-
ment. As seen on figure 5 (bottom panel), before treat-
ment, the majority of cycling cells were effector memory
CD4+ T cells. After treatment, Ki67-expressing EM CD4+
T cell subset was reduced by half and, consistent with the
data obtained for the distribution of subpopulations, in
low dose treated animals, the percentage of Ki67 expres-
sing CD4+ T cells was increased in the central memory
subset (Δ%=+54.8 and 32.5%) while in high dose treated
macaques, this frequency was mostly augmented in the
naïve subset (Δ%=+18.8 and 7%) and, to a lesser extent,
in the central memory subpopulation.
Interestingly, in CD8+ T cells treated with low dose of
rIL-2, the pool of cycling terminal differentiated cells
decreased (Δ%=−10.6 and −4%) whereas it increased when
using high dose (Δ%=+29.1 and 24%); rIL-2 having a mod-
est impact on frequency of cycling EM cells compared to
that observed in CD4+ T cells (Figure 6 – bottom panel).
These results showed that rIL-2 led to a transient in-
crease of the proliferation and activation of CD4 and
CD8 T cell subsets.
Human rIL-2 modulates CD4+ and CD8+ T cell
spontaneous apoptosis
IL-2 has been shown to exert pro- or anti-apoptotic
effects in a variety of hematopoietic cells. Furthermore,
as we observed a transient activation of CD4+ and CD8+ll subset. Ki67 expression was measured intracellularly in CD8+ T cells
N, CM, EM or TD) at days 0 and 7 after IL-2 treatment (bottom panel).
6238 (high dose).
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tion of effector memory and Terminally Differentiated T
cell subsets, we wanted to analyze whether cell death
could be induced in these populations. In this purpose,
we evaluated CD4 and CD8 T cell apoptosis by quantify-
ing cell surface expression of Phosphatidyl Serine resi-
dues by Annexin V staining (Figure 7).
Interestingly, our data revealed opposite effect of low
versus high dose of rIL-2 on CD4+ T cells. Indeed, CD4+
T cells from monkeys treated with the lower dose were
less prone to die than CD4+ T cells from macaques trea-
ted with the higher dose. As seen in figure 7A, animalsFigure 7 Human rIL-2 modulates spontaneous CD4+ and CD8+ T cell
AnnexinV. Total CD4+ (A) and CD8+ (C) T cell apoptosis was measured afte
assess the propensity of each subset to undergo apoptosis, apoptosis was
(N, CM, EM or TD) at day 0 and day 7 after IL-2 treatment. T cells, gated on
analysed for CD45RA and CD62L expression. Each subpopulation (N, CM, E
was calculated as follows for each subset:% AnnexinV+ among subset=N (C
(CM, EM or TD) AnnexinV- T cells) x100.treated with low dose of rIL-2 showed a decrease in the
frequency of apoptotic CD4+ T cells at day 7 compared
with pre treatment values (Δ%=−16.7 and −11.2%)
whereas high dose treated macaques exhibited a robust
increase of CD4+ T cell apoptosis (Δ%=+18.5 and
16.3%). rIL-2 seemed to exert a long term effect on CD4+
T cell death as levels of apoptosis at day 45 remained
either increased (Δ%=+11.7 and 4.3%) or decreased
(Δ%=−17.7 and −13.9%) compared to basal levels in high
or low dose treated animals respectively.
This dose-dependent effect on cell death was also
observed in the CD8 T cell compartment as low doseapoptosis. Apoptotic cell death was assessed using FITC-conjugated
r 16 h of culture at day 0, 7 and 45 after IL-2 treatment. In order to
then measured in each CD4+ (B) or CD8+ (D) T cell subpopulation
lymphocytes gate followed by gating on CD4+ or CD8+ Tcells, were
M and TD) was then assessed for AnnexinV expression and sensitivity
M, EM or TD) AnnexinV+ T cells/ (N (CM, EM or TD) AnnexinV+ T cells+N
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high dose raised frequency of apoptotic CD8+ T cells
by +31.5 and 35.8% in each animal, respectively. Unlike
the effect on CD4 T cell compartment, this increase was
transient (day 7) and frequencies of apoptotic cells
returned to basal levels at day 45 (Figure 7C).
Given that rIL-2 impacted on T cell subsets distribu-
tion, we next analyzed susceptibility to undergo apop-
tosis within each CD4 or CD8 T cell subset. As seen in
figure 7B, rIL-2 mainly exerted its effect, either pro- or
anti-apoptotic, on the central memory CD4+ T cell sub-
population. Indeed, in low dose treated animals, the fre-
quency of apoptotic central memory CD4+ T cells
decreased by a mean of 19.1% at day 7. In macaques
treated with high rIL-2 dose, this frequency rose by a
mean of 20.4%. Treatment with high dose of rIL-2 also
induced an increase in naïve CD4 T cell death at day 7
after injection (from 9.7 and 5.6% to 15 and 14.4% -
mean Δ%=7%). In contrast to this specific effect on cen-
tral memory CD4+ T cells, no difference on CD8 T cells
apoptosis could be observed whatever the rIL-2 dose
used (Figure 7D).
Thus, low dose of rIL-2 seemed to decrease sensitivity
of central memory CD4+ T cells to spontaneous cell
death while high dose of rIL-2 increased sensitivity of
this population to undergo apoptosis. Moreover, while
low dose of rIL-2 had no effect on CD8 T cell apoptosis,
high dose clearly potentiated spontaneous CD8 T cell
death. However, unlike its effect on CD4+ T cells, the
cytokine did not specifically modulate sensitivity of any
CD8 T cell subset but exerted a global effect on each
CD8 T cell subpopulation.
Human rIL-2 has a dose dependent effect on Fas-induced
CD4 and CD8 T cell apoptosis
As we found that, depending on the dose of rIL-2 used,
T cells were more or less sensitive to spontaneous apop-
tosis, we next sought to determine whether this differen-
tial sensitivity was also observed for Fas-induced cell
death. Indeed, we and others have previously shown that
Fas-mediated cell death is associated with progression to
AIDS and chronic immune activation observed in HIV/
SIV disease could drive T cells into apoptosis via Fas/
FasL pathway [25-27].
First, we evaluated cell surface expression of CD95/Fas
on CD4+ and CD8+ T cells. We showed that low dose of
rIL-2 had almost no effect on CD95 cell surface expres-
sion either on CD4+ or CD8+ T cells. On the contrary,
high dose of rIL-2 induced a low increase of CD95 expres-
sion at the surface of CD4+ and CD8+ T cells (data not
shown).
As observed with spontaneous apoptosis, our results
highlighted the dual effect of rIL-2 on Fas-induced CD4+
T cell apoptosis. Indeed, at day 7 after treatment, whenanimals were treated with low dose rIL-2, we observed a
significant decrease in Fas-induced CD4+ T cell apop-
tosis (−26.7 and −6.1%) whereas when treated with high
dose, animals experienced a robust increase in Fas-
induced CD4+ cell death (+30.8 and +14.1%). At high
dose, this rIL-2 proapoptotic effect seemed to be persist-
ent as apoptotic rates were still increased at day 45 com-
pared to baseline (Figure 8A).
Surprisingly, rIL-2 induced a more questionable effect
on CD8+ T cell population as only high dose showed a
reproducible effect in all animals with 20.1 and 16.2%
increases in Fas-induced CD8+ T cell apoptosis at day 7
after treatment (Figure 8C).
Thereafter, we studied sensitivity of each subset to
Fas-induced apoptosis. As shown on Figure 8B, treat-
ment with low dose of rIL-2 induced an overall slight ef-
fect on every CD4 T cell subsets (from −3.5 to −6%
depending on the subset) whereas treatment with high
dose of rIL-2 led to a more contrasting effect. Indeed, it
increased sensitivity of naïve (Δ%=+7.5 and +7.4%) and
central memory (Δ%=+18.5 and +46.8%) subsets while
it decreased sensitivity of effector memory (Δ%=−12.7
and −20.6%) and terminal differentiated (Δ%=−11.3 and
−16.7%) subsets (Figure 8B). Regarding CD8+ T cells, we
showed that treatment with low dose of rIL-2 decreased
sensitivity of naïve CD8+ T cells to Fas-induced apop-
tosis (Δ%=−11.3 and −20.2%) whereas it increased sen-
sitivity of CD8 central memory subset (Δ%=+26.1 and
+12.7%) (Figure 8D). When animals were treated with
high dose of rIL-2, a dramatic increase in sensitivity to
Fas-induced apoptosis was observed in CD8 naïve
(Δ%=+36.2 and +45.6%), central memory (Δ%=+73.3
and +87.4%) and effector memory (Δ%=+61.5 and
+48.8 %) subsets (Figure 8D).
Thus, we showed here that treatment with rIL-2 could
modulate Fas-induced cell death. This modulation was
particularly obvious when rIL-2 was used at high dose
with a strong potentiator effect on Fas-induced CD4
central memory and CD8 naïve, central and effector
memory T cells apoptosis.
Discussion
Both enhanced T cell turnover and survival have been
implicated in regulating the size of the peripheral T
lymphocyte pool following IL-2 immunotherapy in HIV-
infected patients. To date, selective expansion of CD4+ T
cells is considered as the hallmark of IL-2-driven immune
reconstitution. According to the latest data, the increase
of CD4+ T cell count due to IL-2 immunotherapy in ART
treated patients does not confer clinical benefit but may
induce grade 4 clinical side effects [24]. Several hypotheses
were evoked to explain these disappointing results. IL-2
side effects might overcome beneficial effects on host
defenses or the CD4+ T cells induced by IL-2 treatment
Figure 8 Human rIL-2 modulates Fas-mediated CD4+ and CD8+ T cell apoptosis. Fas-induced apoptotic cell death was assessed using
FITC-conjugated AnnexinV. Total CD4+ (A) and CD8+ (C) T cell apoptosis was measured after 16 h of culture in the presence of FasL (200 ng/ml)
at day 0, 7 and 45 after IL-2 treatment. In order to assess the propensity of each subset to undergo apoptosis, apoptosis was then measured in
each CD4+ (B) or CD8+ (D) T cell subpopulation (N, CM, EM or TD) at day 0 and day 7 after IL-2 treatment. T cells, gated on lymphocytes gate
followed by gating on CD4+ or CD8+ Tcells, were analysed for CD45RA and CD62L expression. Each subpopulation (N, CM, EM and TD) was then
assessed for AnnexinV expression and sensitivity was calculated as follows for each subset:% AnnexinV+ among subset=N (CM, EM or TD)
AnnexinV+ T cells/ (N (CM, EM or TD) AnnexinV+ T cells+N (CM, EM or TD) AnnexinV- T cells x100.
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these observations, we wanted to explore the impact of
IL-2 immunotherapy in a model of infection (i.e.: SIV in-
fection of Rhesus macaques) without ART treatment in
order to observe only IL-2-induced changes on various
immunological parameters.
First studies using IL-2 therapy in HIV patients had
shown that this treatment could induce transient
increases in HIV viremia [28] at least due to higher
levels of CCR5 expression [16]. However, other studies
had reported that most of IL-2 treated patients under
ART showed no increase in plasma viral load [29,30].Here, although rIL-2 treatment leads to a dramatic
increase of CD4 T cell subset (including cycling cells
(Ki67+)), plasmatic viral load is not changed in ART
naïve SIV-infected monkeys. These results are consistent
with data previously obtained in our laboratory [30] and
with the UK Vanguard study which showed that inter-
mittent cycles of subcutaneous IL-2 produced significant
increases in CD4 T cell counts without affecting viral
load in ART-naïve HIV-infected patients [31]. Thus,
according to our results, adverse IL-2 effects do not
seem to be due to its effect on HIV viremia, even in the
absence of ART treatment. Therefore, we addressed
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benefit observed in SILCAAT/ESPRIT studies. First, we
studied the effect of IL-2 on CD4 and CD8 subpopula-
tions. Then, we wanted to confirm and extend results
previously obtained in our group [23] concerning IL-2
driven Treg induction. Finally, given the controversial
literature concerning IL-2 and apoptosis, we wanted to
clarify the role of this cytokine on CD4 and CD8 T
lymphocyte cell death in vivo.
First, our data show that treatment of chronically SIV-
infected Rhesus macaques with rIL-2 induced a rapid,
transient, dose-dependent increase in peripheral T cell
counts at day 7 after treatment. This immunotherapy not
only induces CD4+ T cell expansion but also affects CD8+
T cell pool early after treatment. These results are consist-
ent with data obtained following IL-2 immunotherapy in
metastatic melanoma patients in which levels of perforin
and granzyme - which are essential for CD8+ T cell cyto-
toxicity - were increased [32]. Since then, many other
studies have shown that IL-2 immunotherapy mediated
tumor regression via enhanced endogenous tumor specific
CD8+ responses [33,34]. Nevertheless, a dramatic CD4
lymphopenia occurred at day 45 in all treated animals
while CD8+ T cell loss only occurred in high dose treated
animals.
We demonstrate that treatment with low or high dose
of rIL-2 has a differential effect on CD4 and CD8 T cell
subpopulations repartition. Indeed, regarding CD4 T cell
subsets, the higher dose of rIL-2 selectively expanded
naïve and central memory compartments whereas low
dose only affected memory populations (central and ef-
fector). These rIL-2 selectively expanded CD4+ T cells
are activated and express proliferation markers. These
cells are most likely new thymic emigrants as it was
strongly suggested that a naive T-cell increase reflected
thymic export after IL-2 therapy in HIV-infected
patients [35]. In addition, while low dose seemed to
exert a transient effect, higher dose induced a sustained
effect as changes observed in subsets distribution were
maintained at day 45 after treatment. Finally, both doses
induced a drastic depletion of terminally differentiated
CD4+ T cells (at day 45 after treatment) associated with
the occurrence of a wasting syndrome characterized by
weight loss and diarrhea. These results are consistent
with data obtained in the UK-Vanguard trial which sug-
gested that after IL-2 discontinuation, CD4 T cell counts
declined rapidly even below therapeutic threshold [36].
We therefore propose that although rIL-2 contributes to
correct the HIV-driven unbalance within naïve and cen-
tral memory CD4+ T compartments, it also leads, in the
absence of antiretroviral treatment, to T cell exhaustion
and immune failure through excessive expansion, prolif-
eration, activation and apoptosis of CD4 naïve and cen-
tral memory subsets.IL-2 is well-known as a key regulator of immune tol-
erance as it promotes the development and peripheral
expansion of CD4+ CD25high Tregs. In the context of
HIV, several reports have suggested that Tregs may have
a beneficial role either by suppressing viral replication
or by limiting non specific activation [37,38]. On the
contrary, other studies suggested that Tregs may ac-
count for premature and persistent suppression of ef-
fector response, thus contributing to establishment of a
chronic disease state. Indeed, Tregs have been shown to
inhibit HIV-specific T-cell responses ex vivo and may
act in vivo by suppressing HIV-specific immunity, allow-
ing HIV to persist [39-42]. We have recently reported
that, following IL-2 immunotherapy, resting and acti-
vated Tregs were expanded in HIV-infected patients
under HAART regimen [23]. They suggest that these
CD4+ Tregs may inhibit the generation of responses
against pathogens thereby providing a beginning of ex-
planation for the disappointing results of ESPRIT and
SILCAAT studies. We largely confirm and extend these
results in our model as rIL-2, at low dose, drives a
massive, transient peripheral CD4 Treg expansion. At
day 45, however, size of the CD4 Treg compartment
returns to baseline value (low dose treatment) or is even
decreased compared to baseline (high dose treatment).
This decrease in peripheral blood may reflect relocation
of CD4 Tregs in lymphoid tissues, particularly in the
gut [43], thus strengthening loss of the Th17/Treg cell
balance that is already observed in progressive HIV/SIV
infection associated with the expression of TGF-β [44-47].
Concerning Treg populations, we also show that treatment
with rIL-2 induces a sustained and dose-dependent periph-
eral expansion of a poorly studied population, namely
CD8+ Tregs. These results are consistent with the
study of Nigam et al. who recently demonstrated that
peripheral CD8+CD25highFoxP3+ T cells were induced
early after SIV infection and that the number of these
cells was positively correlated with viral load and asso-
ciated with a poor prognosis. This rapid expansion of
CD8 Tregs in the blood was also observed in multiple
lymphoid tissues of SIV-infected Rhesus macaques but
not in non pathogenic SIV infection of Sooty Manga-
beys. Moreover, they showed that these cells were able
to suppress antiviral immunity thereby suggesting a
deleterious role for this CD8+ T cell subset during the
course of the disease [48]. In addition, following treat-
ment with rhIL-2, a dramatic increase in CD8+ Foxp3+
T cell prevalence was observed in the circulation and
tumor-draining lymph nodes of subcutaneous tumor-
bearing mouse models [49]. Effect of rIL-2 on the T
regulatory compartment thus provides a first piece of
explanation for the rapid development of wasting syn-
drome in our animals. Indeed, rIL-2 may act, on the
one hand, on CD4 Treg population, inducing its
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tissues (GALT) thereby contributing to loss of Th17/
Treg balance. On the other hand, rIL-2 provokes per-
ipheral expansion of CD8+ Treg subset contributing to
defective antiviral immunity.
Finally, our study underlines the dual role of IL-2 in
the context of spontaneous and Fas-induced apoptosis.
Several groups have already investigated the effect of
IL-2 immunotherapy on apoptosis but results were quite
discordant. Indeed, it was shown that, in HIV-infected
patients, IL-2 treatment was associated with increased
apoptosis rates [50]. On the opposite, some studies
showed that IL-2 could reduce lymphocyte apoptosis in
HIV infected patients [51]. Here, we report that IL-2 can
effectively play both role depending on the dose used,
high dose having a proapoptotic effect on both CD4+
and CD8+ T cells and low dose being antiapoptotic in
CD4+ T cells only. This modulating effect on cell death
seems to be restricted to CD4+ central memory T cells
while it exerts a global effect on each CD8+ T cell sub-
sets. Excessive apoptosis observed in high dose treated
animals could be due to higher expression of Fas recep-
tor on CM CD4+ T lymphocytes cell surface, indeed we
observed that Fas expression on CD4+ T lymphocytes
was increased after rIL-2 treatment (data not shown).
We and others have reported that T cells from HIV-
infected individuals or SIV-infected macaques are highly
prone to undergo apoptosis after Fas-ligation [6-8,27]. A
recent study showed that Rhesus macaques treated with
neutralizing anti-FasL antibody preserved higher levels
of central memory CD4+ T cells [52] thereby supporting
a critical role for Fas in the CD4+ T cell compartment.
Herein, we found that in vivo IL-2 treatment has a detri-
mental effect on the susceptibility of cells to undergo
apoptosis after Fas ligation. However, we cannot exclude
a role for other death molecules like PD-1 or TRAIL
that have been proposed to participate in the death of T
cells during HIV/SIV infection [46,53-56]. Further inves-
tigation of these cell death pathways among various
lymphoid populations should provide new insights
about immunological mechanisms implicated in IL-2
immunotherapy.
Conclusions
Following rIL-2 treatment in SIV-infected Rhesus maca-
ques, T cells - including CD4 and CD8 Tregs - are there-
fore not only expanded but, in addition, become more
susceptible to undergo apoptosis providing a rational for
disease progression. Thus, our data contribute to the
understanding of the homeostatic and dosage effects of
IL-2 in the context of SIV/HIV infection. Although the
conclusions drawn in SIV monkey models are not easy
to translate to human infected with HIV, we believe that
our data provide new insights in this field regarding theimportant and long term commitment in developing
IL-2 therapy.Methods
Animals
Rhesus Macaques (Macaca mulatta) of Chinese origin
were inoculated intravenously with 10 AID50 (50% ani-
mal infectious dose) of the SIVmac251 strain. All the ani-
mals were challenged with the same batch of virus
(provided by AM. Aubertin, INSERM U74, Strasbourg,
France), titrated in vivo in RMs, and stored in liquid ni-
trogen. Animals were seronegative for simian T leukemia
virus type 1, SRV-1 (type D retrovirus), herpesvirus B,
and SIVmac. Animals were housed and cared for in com-
pliance with existing French regulations (Institut Pasteur,
Paris, France). All the animal experiments described in
the present study were conducted at the Institut Pasteur
according to the European Union guidelines for the
handling of laboratory animals (http://ec.europa.eu/
environment/chemicals/lab_animals/home_en.htm). The
protocol was approved by the committee on the ethics of
animal experiments of Ile de France. All surgery was per-
formed under sodium pentobarbital anesthesia, and all
efforts were made to minimize suffering. Macaques in
chronic phase of infection were then either treated with
6.105 UI/kg body weight (high dose), 1.4.105 UI/kg body
weight (low dose) recombinant human IL-2 (MacrolinW
Aldesleukine rhIL-2) or saline solution (control) daily for
5 days. Blood samples were collected before IL-2 treat-
ment (day 0) and at day 7, 10, 15, 30 and 45 after
treatment.Lymphocyte immunophenotyping and flow cytometry
Blood from monkeys was collected in sterile EDTA-
treated vacuum tubes and cell populations were analyzed
by flow cytometry using the following antibodies: anti-
CD20-FITC (clone 2 H7), anti-CD4-PE (clone L200),
anti-CD62L-FITC (clone SK11), anti-CD62L-PE (clone
SK11), anti-CD25-PE (clone M-A251), anti-CD3-PerCP
(clone SP34-2), anti-CD4-PerCP (clone SK3), anti-
human CD8-PerCP (clone SK1), anti-CD8-APC (clone
RPA-T8), anti-CD95-APC (clone DX2) and anti-CD127-
Alexa 647 (clone HIL-7R-M21) were purchased from BD
Biosciences/Pharmingen (San Jose, CA). Anti-CD45RA-
APC (clone T6D11) was obtained from Miltenyi (Bergisch
Gladbach, Germany). For intracellular staining, the cells
were fixed and permeabilized before incubation with anti-
Ki67-FITC (clone Ki67, Dako, Glostrup, Denmark), or anti-
Fox-P3-Alexa 488 (clone 259D/C7, BD Pharmingen, San
Jose, CA).
Cells were analyzed by flow cytometry. A total of
30000 events in the lymphocyte gate were analyzed
using CellQuest software (BD Biosciences). All analyses
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Biosciences).
Cell death quantification
PBMCs from monkeys were isolated from peripheral
blood by density gradient centrifugation LymphoPrep
(PAA Laboratories, Pasching, Austria) and cultured in
RPMI 1640 supplemented with 10% FCS, 1% glutamine,
1% pyruvate, and 1% antibiotics. Up to 500,000 PBMCs
were cultured overnight in the absence or presence of
recombinant Fas-L (10 μg/ml, Alexis Corporation). Cell
death was assessed by flow cytometry, as previously
described [8]. Briefly, after staining with specific anti-
bodies (30 min at 4°C), cells were washed and then incu-
bated with FITC labeled Annexin-V (10 min at 4°C), and
30000 events were analyzed with a FACScalibur flow
cytometer (BD Biosciences).
Viral quantification
RNA was extracted from plasma of SIV-infected mon-
keys using the TRI Reagent BD Kit (Molecular Research
Center, Cincinnati, OH). Real-time quantitative RT-PCR
was used to determine viral loads as previously described
[57].
Additional file
Additional file 1: Human rIL-2 does not affect hematological
parameters. Four Rhesus macaques were infected with the pathogenic
SIVmac251 strain and then treated during chronic phase with human
rIL-2 (low dose: ○,Δ or high dose: ●,▲). Each symbol represents one
individual. Hematological and physiological parameters such as platelet
erythrocyte counts, hematocrit, temperature, weight were measured at
the day of treatment and thereafter.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JG carried out the experimental work and wrote the paper. ML carried out
the viral quantification experiments. RS, SM and LCG helped with the
monkeys. YL and JE conceived the study, oversaw its execution and edited
the manuscript. All authors read and approved the final manuscript.
Funding information
This study was supported by research funding from the ANRS to JE and YL
and the “Fondation pour la Recherche Médicale”, to JE. JG and ML were
supported by fellowships from ANRS, SM by SIDACTION and RS by a
fellowship from the FCT program Ciência 2008.
Author details
1INSERM U955 Equipe 16, Institut Mondor de Recherche Biomédicale,
CréteilF-94010, France. 2Université Paris-Est, Faculté de Médecine, UMR-S 955,
Créteil F-94010, France. 3Assistance Publique-Hôpitaux de Paris (AP-HP),
Groupe Henri-Mondor Albert-Chenevier, service d’immunologie clinique,
Créteil F-94010, France. 4CNRS FRE 3235, Université Paris Descartes, Paris,
France. 5Université Laval, Centre de recherche en Infectiologie, Québec,
Canada. 6Instituto de Biologia Molecular e Celular, Universidade do Porto,
Porto, Portugal.
Received: 3 February 2012 Accepted: 14 September 2012
Published: 28 September 2012References
1. Hurtrel B, Petit F, Arnoult D, Muller-Trutwin M, Silvestri G, Estaquier J:
Apoptosis in SIV infection. Cell Death Differ 2005, 12(Suppl 1):979–990.
2. Giralt M, Diaz-Delfin J, Gallego-Escuredo JM, Villarroya J, Domingo P,
Villarroya F: Lipotoxicity on the basis of metabolic syndrome and
lipodystrophy in HIV-1-infected patients under antiretroviral treatment.
Curr Pharm Des 2010, 16:3371–3378.
3. Veloso S, Peraire J, Vilades C, Lopez-Dupla M, Escote X, Olona M, Garcia-
Pardo G, Gomez-Bertomeu F, Soriano A, Sirvent JJ, Vidal F:
Pharmacogenetics of the metabolic disturbances and atherosclerosis
associated with antiretroviral therapy in HIV-infected patients. Curr
Pharm Des 2010, 16:3379–3389.
4. Muro-Cacho CA, Pantaleo G, Fauci AS: Analysis of apoptosis in lymph
nodes of HIV-infected persons. Intensity of apoptosis correlates with the
general state of activation of the lymphoid tissue and not with stage of
disease or viral burden. J Immunol 1995, 154:5555–5566.
5. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML: Differential
susceptibility to activation-induced apoptosis among peripheral Th1
subsets: correlation with Bcl-2 expression and consequences for AIDS
pathogenesis. J Immunol 1998, 160:3194–3206.
6. Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, Ameisen JC:
T helper type 1/T helper type 2 cytokines and T cell death: preventive
effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-
mediated apoptosis of CD4+ T cells from human immunodeficiency
virus-infected persons. J Exp Med 1995, 182:1759–1767.
7. Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC: Fas-
mediated apoptosis of CD4+ and CD8+ T cells from human
immunodeficiency virus-infected persons: differential in vitro preventive
effect of cytokines and protease antagonists. Blood 1996, 87:4959–4966.
8. Arnoult D, Petit F, Lelievre JD, Lecossier D, Hance A, Monceaux V, Hurtrel B,
Ho Tsong Fang R, Ameisen JC, Estaquier J: Caspase-dependent and
-independent T-cell death pathways in pathogenic simian
immunodeficiency virus infection: relationship to disease progression.
Cell Death Differ 2003, 10:1240–1252.
9. Boudet F, Lecoeur H, Gougeon ML: Apoptosis associated with ex vivo
down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic
CD8+ T lymphocytes during HIV infection. J Immunol 1996,
156:2282–2293.
10. Zaunders JJ, Moutouh-de Parseval L, Kitada S, Reed JC, Rought S, Genini D,
Leoni L, Kelleher A, Cooper DA, Smith DE, et al: Polyclonal proliferation
and apoptosis of CCR5+ T lymphocytes during primary human
immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2,
IL-15, and Bcl-2. J Infect Dis 2003, 187:1735–1747.
11. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML:
Alteration of tumor necrosis factor-alpha T-cell homeostasis following
potent antiretroviral therapy: contribution to the development of human
immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000,
95:3191–3198.
12. Lenardo MJ: Interleukin-2 programs mouse alpha beta T lymphocytes for
apoptosis. Nature 1991, 353:858–861.
13. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I: Development and
function of T cells in mice rendered interleukin-2 deficient by gene
targeting. Nature 1991, 352:621–624.
14. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS:
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce
the expression of programmed death-1 and its ligands. J Immunol 2008,
181:6738–6746.
15. Petit F, Arnoult D, Lelievre JD, Moutouh-de Parseval L, Hance AJ, Schneider
P, Corbeil J, Ameisen JC, Estaquier J: Productive HIV-1 infection of primary
CD4+ T cells induces mitochondrial membrane permeabilization leading
to a caspase-independent cell death. J Biol Chem 2002, 277:1477–1487.
16. Zou W, Foussat A, Houhou S, Durand-Gasselin I, Dulioust A, Bouchet L,
Galanaud P, Levy Y, Emilie D: Acute upregulation of CCR-5 expression by
CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2.
ANRS 048 IL-2 study group. AIDS 1999, 13:455–463.
17. Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C,
Rouzioux C, Resch M, Guillet JG, Kazatchkine M, et al: Sustained control of
viremia following therapeutic immunization in chronically HIV-1-infected
individuals. AIDS 2006, 20:405–413.
18. Gougeon ML, Rouzioux C, Liberman I, Burgard M, Taoufik Y, Viard JP,
Bouchenafa K, Capitant C, Delfraissy JF, Levy Y: Immunological and
Garibal et al. Virology Journal 2012, 9:220 Page 14 of 15
http://www.virologyj.com/content/9/1/220virological effects of long term IL-2 therapy in HIV-1-infected patients.
AIDS 2001, 15:1729–1731.
19. Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, Masur H,
Follmann DA, Lane HC, Davey RT Jr: Induction and maintenance therapy
with intermittent interleukin-2 in HIV-1 infection. Blood 2004,
103:3282–3286.
20. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C,
Oksenhendler E, Weiss L, Gastaut JA, et al: Effects of interleukin-2 therapy
combined with highly active antiretroviral therapy on immune
restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003,
17:343–351.
21. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly
G, Metcalf JA, Davey RT Jr, Falloon J, et al: Induction of prolonged survival
of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected
patients. J Clin Invest 2005, 115:2139–2148.
22. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y,
Berg SC, Metcalf JA, Hahn BK, Shen JM, et al: In vivo expansion of
CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected
patients. J Clin Invest 2005, 115:1839–1847.
23. Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B,
Benecke A, Rogge L, Levy Y: In vivo expansion of naive and activated
CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-
treated HIV patients. Proc Natl Acad Sci USA 2010, 107:10632–10637.
24. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J,
Emery S, Fox L, Gordin F, et al: Interleukin-2 therapy in patients with HIV
infection. N Engl J Med 2009, 361:1548–1559.
25. Marshak-Rothstein A, Stanger BZ, Sherr DH, Ju ST, Panka DJ, Cui H, Ettinger
R, Khatib M: as(CD95)/FasL interactions required for programmed cell
death after T-cell activation. Nature 1995, 373:444–448.
26. Lelievre JD, Mammano F, Arnoult D, Petit F, Grodet A, Estaquier J, Ameisen
JC: A novel mechanism for HIV1-mediated bystander CD4+ T-cell death:
neighboring dying cells drive the capacity of HIV1 to kill noncycling
primary CD4+ T cells. Cell Death Differ 2004, 11:1017–1027.
27. Viollet L, Monceaux V, Petit F, Ho Tsong Fang R, Cumont MC, Hurtrel B,
Estaquier J: Death of CD4+ T cells from lymph nodes during primary
SIVmac251 infection predicts the rate of AIDS progression. J Immunol
2006, 177:6685–6694.
28. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, Polis MA,
Walker RE, Stevens R, Salzman NP, et al: ncreases in CD4 T lymphocytes
with intermittent courses of interleukin-2 in patients with human
immunodeficiency virus infection. A preliminary study. N Engl J Med
1995, 332:567–575.
29. Go R, Steigbigel R: Interleukin 2 and HIV RNA Levels. Arch Intern Med 2007,
167:2144–2145. author reply 2145.
30. Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon
ML, Venet A, Madelaine I, Sereni D, et al: Interleukin-2 before antiretroviral
therapy in patients with HIV infection: a randomized trial (ANRS 119). J
Infect Dis 2009, 200:206–215.
31. Youle M, Emery S, Fisher M, Nelson M, Fosdick L, Janossy G, Loveday C,
Sullivan A, Herzmann C, Wand H, et al: A randomised trial of
subcutaneous intermittent interleukin-2 without antiretroviral therapy in
HIV-infected patients: the UK-Vanguard study. PLoS Clin Trials 2006, 1:e3.
32. Leger-Ravet MB, Mathiot C, Portier A, Brandely M, Galanaud P, Fridman WH,
Emilie D: Increased expression of perforin and granzyme B genes in
patients with metastatic melanoma treated with recombinant
interleukin-2. Cancer Immunol Immunother 1994, 39:53–58.
33. Romano F, Piacentini MG, Franciosi C, Caprotti R, De Fina S, Cesana G,
Uggeri F, Conti M, Uggeri F: Phase-II randomized study of preoperative
IL-2 administration in radically operable gastric cancer patients.
Hepatogastroenterology 2004, 51:1872–1876.
34. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D,
Robinson BW, Nelson DJ: IL-2 intratumoral immunotherapy enhances CD8
+ T cells that mediate destruction of tumor cells and tumor-associated
vasculature: a novel mechanism for IL-2. J Immunol 2003,
171:5051–5063.
35. Carcelain G, Saint-Mezard P, Altes HK, Tubiana R, Grenot P, Rabian C, de
Boer R, Costagliola D, Katlama C, Debre P, Autran B: IL-2 therapy and
thymic production of naive CD4 T cells in HIV-infected patients with
severe CD4 lymphopenia. AIDS 2003, 17:841–850.
36. Herzmann C, Cuthbertson Z, Fosdick L, Fisher M, Nelson M, Perry N, Law M,
Wand H, Janossy G, Johnson MA, Youle M: Long-term clinical andsurrogate marker effects of subcutaneous intermittent interleukin-2
without antiretroviral therapy in HIV-infected patients. J Antimicrob
Chemother 2008, 62:583–586.
37. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF: Preservation of
FoxP3+ regulatory T cells in the peripheral blood of human
immunodeficiency virus type 1-infected elite suppressors correlates with
low CD4+ T-cell activation. J Virol 2008, 82:8307–8315.
38. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA: Regulatory T
cells control HIV replication in activated T cells through a cAMP-
dependent mechanism. Blood 2011, 117:5372–5380.
39. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF: Human
CD4+ CD25+ regulatory T cells control T-cell responses to human
immunodeficiency virus and cytomegalovirus antigens. J Virol 2004,
78:2454–2459.
40. Kinter A, McNally J, Riggin L, Jackson R, Roby G, Fauci AS: Suppression of
HIV-specific T cell activity by lymph node CD25+ regulatory T cells from
HIV-infected individuals. Proc Natl Acad Sci USA 2007, 104:3390–3395.
41. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y:
Human immunodeficiency virus-driven expansion of CD4+CD25+
regulatory T cells, which suppress HIV-specific CD4 T-cell responses in
HIV-infected patients. Blood 2004, 104:3249–3256.
42. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, McElrath
MJ, Horton H: Protective HIV-specific CD8+ T cells evade Treg cell
suppression. Nat Med 2011, 17:989–995.
43. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB,
Somsouk M, Deeks SG, Shacklett BL: Increased frequency of regulatory T
cells accompanies increased immune activation in rectal mucosae of
HIV-positive noncontrollers. J Virol 2011, 85:11422–11434.
44. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson
L, Barbour JD, Baskin CR, et al: Critical loss of the balance between Th17
and T regulatory cell populations in pathogenic SIV infection. PLoS
Pathog 2009, 5:e1000295.
45. Estes JD, Li Q, Reynolds MR, Wietgrefe S, Duan L, Schacker T, Picker LJ,
Watkins DI, Lifson JD, Reilly C, et al: Premature induction of an
immunosuppressive regulatory T cell response during acute simian
immunodeficiency virus infection. J Infect Dis 2006, 193:703–712.
46. Cumont MC, Monceaux V, Viollet L, Lay S, Parker R, Hurtrel B, Estaquier J:
TGF-beta in intestinal lymphoid organs contributes to the death of
armed effector CD8 T cells and is associated with the absence of virus
containment in rhesus macaques infected with the simian
immunodeficiency virus. Cell Death Differ 2007, 14:1747–1758.
47. Campillo-Gimenez L, Cumont MC, Fay M, Kared H, Monceaux V, Diop O,
Müller-Trutwin M, Hurtrel B, Lévy Y, Zaunders J, Dy M, Leite-de-Moraes MC,
Elbim C, Estaquier J: AIDS progression is associated with the emergence
of IL-17-producing cells early after simian immunodeficiency virus
infection. J Immunol 2010, 184:984–92.
48. Nigam P, Velu V, Kannanganat S, Chennareddi L, Kwa S, Siddiqui M, Amara
RR: Expansion of FOXP3+ CD8 T cells with suppressive potential in
colorectal mucosa following a pathogenic simian immunodeficiency
virus infection correlates with diminished antiviral T cell response and
viral control. J Immunol 2010, 184:1690–1701.
49. Foureau DM, McKillop IH, Jones CP, Amin A, White RL, Salo JC: Skin tumor
responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell
expansion in an immunocompetent mouse model. Cancer Immunol
Immunother 2011, 60:1347–1356.
50. Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs
JA, Davey RT, Lane HC: CD4 T cell expansions are associated with
increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV
infected patients. AIDS 2001, 15:1765–1775.
51. Pandolfi F, Pierdominici M, Marziali M, Livia Bernardi M, Antonelli G, Galati V,
D'Offizi G, Aiuti F: Low-dose IL-2 reduces lymphocyte apoptosis and
increases naive CD4 cells in HIV-1 patients treated with HAART. Clin
Immunol 2000, 94:153–159.
52. Poonia B, Salvato MS, Yagita H, Maeda T, Okumura K, Pauza CD: Treatment
with anti-FasL antibody preserves memory lymphocytes and
virus-specific cellular immunity in macaques challenged with simian
immunodeficiency virus. Blood 2009, 114:1196–1204.
53. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B,
Boulassel MR, Delwart E, Sepulveda H, Balderas RS, et al: Upregulation of
PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune
dysfunction. Nat Med 2006, 12:1198–1202.
Garibal et al. Virology Journal 2012, 9:220 Page 15 of 15
http://www.virologyj.com/content/9/1/22054. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey
EW, Miller JD, Leslie AJ, DePierres C, et al: PD-1 expression on HIV-specific
T cells is associated with T-cell exhaustion and disease progression.
Nature 2006, 443:350–354.
55. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC,
Precopio ML, Schacker T, Roederer M, Douek DC, Koup RA: PD-1 is a
regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med
2006, 203:2281–2292.
56. Laforge M, Campillo-Gimenez L, Monceaux V, Cumont MC, Hurtrel B, Corbeil
J, Zaunders J, Elbim C, Estaquier J: HIV/SIV infection primes monocytes
and dendritic cells for apoptosis. PLoS Pathog 2011, 7:e1002087.
57. Monceaux V, Viollet L, Petit F, Ho Tsong Fang R, Cumont MC, Zaunders J,
Hurtrel B, Estaquier J: CD8+ T cell dynamics during primary simian
immunodeficiency virus infection in macaques: relationship of effector
cell differentiation with the extent of viral replication. J Immunol 2005,
174:6898–6908.
doi:10.1186/1743-422X-9-220
Cite this article as: Garibal et al.: IL-2 immunotherapy in chronically SIV-
infected Rhesus Macaques. Virology Journal 2012 9:220.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
